Download presentation
Presentation is loading. Please wait.
Published byBraedon Slaton Modified over 9 years ago
1
First clinical results with αβ+ T-cell depleted haploidentical stem cells in children Children’s University Hospital, Tübingen, Germany P Lang, T Feuchtinger, HM Teltschik, P Schlegel, M Schumm, P Schwarze, M Pfeiffer, K Schilbach, R Handgretinger
2
Haploidentical donors : T cell depletion mandatory 1.CD34+ Selection „pure stem cells“ 2. CD3/19 Depletion Stem cells + effectors (NK cells) 3. TCRαβ/CD19 Depletion Stem cells + effectors (NK cells + γδT cells) 4. Antigen- specific T cells + + 1995 2011
3
The anti-leukemic activity of gamma/delta T-cells Otto M. et al: Human γδT cells from G-CSF mobilized donors retain strong tumoricidal activity and produce immunostimulatory cytokines after clinical scale isolation. J Immunotherapy 2005: 28: 73 Godder et al., Long term disease-free survival in acute leukemic patients recovering with increased γδT cells after partially mismatched related donor bone marrow transplantation. BMT 2007; 39,751-757.
4
magnet waste ( T cells) 1. biotin-anti- mAb 2. microbeads with anti-biotin mAb graft T-cells CD34+ and CD34- progenitors NK cells dendritic cells Strategy for depletion of + T-cells Chaleff S. et al.: A large scale method for the selective Depletion of / T-lymphocytes from PBSC for allogeneic Transplantation. Cytotherapy, 2007
5
TCR depletion: Efficacy of procedure n = 9BeforeAfterLog Depletion Percent TCR 29.2 ± 6.40.0015 ± 0.0008 absolute TCR + 1.4 ± 0.52 x10 10 0,38 ± 0.22 x10 6 4.6 ± 0.3 absolute CD3+ 1.4 ± 0.44 x10 10 3.5 ± 1.8 x10 8 1.6 ± 0.2 absolute CD19+ 2.7 ± 1.4 x10 9 5.3 ± 5.8 x10 6 3.9 ± 0.6
6
n=49 Comparative analysis of the efficacy of T-cell depletion CD34+ selection vs CD3- vs TcR -depletion 4.6 log
7
Graft composition after TCR /CD19 depletion (n=24 patients) CD34+ x10 6 /kg CD3+ x106/kg CD19+ x10 3 /kg CD56+ x10 6 /kg CD14+ x10 6 /kg aßTcR+ x10 3 /kg TcR+ x10 6 /kg min54.646353511.65 max3841.8528192.281146.430 median1213.6110107.461818.911
8
Patients (pediatric, n=24) Diagnosisn= ALL12 AML/MDS/JMML7 Nonmalignant4 Solid tumors1 Disease statusn= CR2-CR68 (35%) NR/active disease11 (48%) 2 nd /3 rd SCT16 (70%)
9
ATG-F (15 mg/kg) 1mg4 mg5 mg -1211109876543+1210 Fludarabin (mg/m²) or Clofarabin 40mg Thiotepa (mg/kg) 10mg Melphalan (mg/m²) 70mg TCR /CD19 depleted cells days from transplantation Conditioning regimen (2) n=12 steroids MMF, if >25.000 residual abT cells
10
TCR /CD19 Depletion: Engraftment
11
TCR /CD19 Depletion: residual T-cells do not cause GvHD (22/24 patients without pharmacological immune suppression) acute GvHD graden=% no GvHD521 °11250 °2312 °3312 °414
12
TCR /CD19 Depletion: Outcome Alive: 17 out of 24 patients (70%) Median Follow up: 0.5 (0.06-1.4) years
13
Comparison of CD3+ recovery: CD3/19 vs TCR /CD19 Depletion
14
Comparison of CD3+ recovery at day +30 p<0.0001 CD3/19 n = 45 TcRab n = 19
15
Comparison of CD3+ recovery: CD3/19 vs TCR /CD19 Depletion p<0.01
16
T cell recovery after TCR Depletion
18
TCR -Depletion results in grafts with high numbers of effector cells ( T cells, NK cells) Robust engraftment Profound depletion of T cells: prevents GvHD in HLA mismatched trp Immune recovery seems to be signifcantly faster than after other graft manipulation procedures Conclusions
19
University Children´s Hospital Tübingen: Tobias Feuchtinger Heiko-Manuel Teltschik Michael Schumm Patrick Schlegel Matthias Pfeiffer Philip Schwarze Martin Ebinger Karin Schilbach Rupert Handgretinger
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.